Maldives world's 1st country to eliminate mother-to-child transmission of HIV, syphilis and hepatitis B
How common are errors in IVF labs? Can they be prevented?
The news of a woman unknowingly giving birth to another patient’s baby after an embryo mix-up at a Brisbane IVF lab has made headlines in Australia and around the world. The distress this incident will have caused to everyone involved is undoubtedly significant.
A report released by Monash IVF, the company which operates the Brisbane clinic, states it “adheres to strict laboratory safety measures (including multi-step identification processes) to safeguard and protect the embryos in its care”.
It also says the company’s own initial investigation concluded the incident was “the result of human error”.
An independent investigation will follow which presumably will shed light on how human error could occur when multi-step identification processes are in place.
On a broader level, this incident raises questions about how common IVF errors are and to what extent they’re preventable.
The booming IVF industry
Because people have children later in life than they used to, some struggle to conceive and turn to assisted reproductive technologies. These include in-vitro fertilisation (IVF) and intracytoplasmic sperm injection (ICSI) which both involve handling of sperm and eggs (gametes) in the laboratory to form embryos. If there’s more than one embryo available after a treatment cycle, they can be frozen and stored for later use.
Increasingly, assisted reproductive technologies are also being used by single women, same-sex couples, and women who freeze their eggs to preserve their fertility.
For these reasons, the fertility industry is booming. In 2022 there were more than 100,000 assisted reproductive treatment cycles performed in Australian fertility clinics, up more than 25% on the number of cycles performed in 2017.
Regulation of the IVF industry
In Australia, the IVF industry is more regulated than in many other parts of the world.
To operate, clinics must be licensed by the Reproductive Technology Accreditation Committee and adhere to its code of practice.
In relation to storage and accurate identification of embryos, the code states clinics must provide evidence of the implementation and review of:
Policies and procedures to identify when, how and by whom the identification, matching, and verification are recorded for gametes, embryos and patients at all stages of the treatment process including digital and manual record-keeping.
The code further states clinics must report serious adverse events to the Reproductive Technology Accreditation Committee. The list of what’s considered a serious adverse event includes any incident that “arises from a gamete or embryo identification mix up”.
Clinics must also adhere to the National Health and Medical Research Council’s ethical guidelines on the use of reproductive technology in clinical practice and research.
Lastly, states and territories have laws that regulate aspects of the IVF industry such as requirements to report adverse events and other data to state authorities.
In the United Kingdom, the Human Fertilisation and Embryology Authority regulates the IVF industry and requires clinics to report adverse incidents. These are reported as grade A, B or C, where A is the most serious and involves “severe harm to one person, or major harm to many”. Data on adverse incidents is reported in a publicly available annual report.
In the United States, however, the IVF industry is largely unregulated, and clinics don’t have to report adverse incidents. However, the American Society for Reproductive Medicine states clinics should have rigorous procedures to prevent the loss, damage, or misdirection of gametes and embryos and have an ethical obligation to disclose errors to all impacted patients.
How common are IVF errors?
There’s no global data on IVF errors so it’s not possible to know how common they are. But we learn about some of the more serious incidents when they’re reported in the media.
While the recent embryo mix-up is the first known incident of this nature in Australia’s 40-year IVF history, we have seen reports of other errors in Australian clinics. These include the alleged use of the wrong donor sperm, embryos being destroyed due to contamination, and inaccurate genetic testing which resulted in the destruction of potentially viable embryos.
In the UK, the Human Fertilisation and Embryology Authority’s most recent report states there was one Grade A incident in 2023–24. This was the first Grade A incident reported since 2019–20 when there were two.
In the US, some notable errors include storage tank malfunctions in two clinics which destroyed thousands of eggs and embryos.
Lawsuits have also been filed for embryo mix-ups. In a 2023 case, a woman from Georgia delivered a Black baby even though she and her sperm donor are both white. The biological parents subsequently demanded custody of the child. Despite wanting to raise him the woman who had given birth gave up the five-month-old boy to avoid a legal fight she couldn’t win, she said.
In the US, some argue most errors go unreported because reporting is not mandated and due to the absence of meaningful regulation.
Are IVF errors preventable?
Despite Australia’s stringent regulation and oversight of the IVF industry, an incident with far-reaching psychological and potentially legal consequences has occurred.
Until the independent investigation reveals how “human error” caused this mix-up, it’s not possible to say what additional measures Monash IVF should take to ensure this never happens again.
An IVF laboratory is a high-pressure environment, and any investigation should look at whether staffing levels are adequate. Staff training is also relevant, and it’s essential all junior lab staff have adequate supervision.
Finally, perhaps Australia should adopt the UK’s model and make data about adverse events reported to the Reproductive Technology Accreditation Committee available to the public in an annual report. To reassure the public, this report could include what measures clinics take to avoid the errors happening again.![]()
Karin Hammarberg, Adjunct Senior Research Fellow, Global and Women's Health, School of Public Health & Preventive Medicine, Monash University
This article is republished from The Conversation under a Creative Commons license. Read the original article.
US reports over 17,000 monkeypox cases
Now virus hits Modi’s family, aunt Narmadaben dies of Covid-19

Sputnik vaccines reliable as AK-47 rifle: Putin

'Everything falls on my shoulders': SII CEO Adar Poonawalla on vaccine pressure in India
MAY 01, 2021 LONDON: Serum Institute of India CEO Adar Poonwalla on Saturday spoke out about the pressures he was under over the production of COVID-19 vaccines to meet the ever-increasing demand in India as the country battles through a devastating second wave of the coronavirus pandemic. In his first comments since he was provided with ‘Y' category security by the Indian government earlier this week, Poonawalla told ‘The Times' in an interview about receiving aggressive calls from some of the most powerful people in India, demanding supplies of Covishield -- the Oxford/AstraZeneca COVID-19 vaccine that the Serum Institute is producing in India. That pressure is largely behind his decision to fly into London to be with his wife and children, the 40-year-old entrepreneur said. "I'm staying here (London) an extended time because I don''t want to go back to that situation. Everything falls on my shoulders but I can''t do it alone...I don't want to be in a situation where you are just trying to do your job, and just because you can't supply the needs of X, Y or Z you really don't want to guess what they are going to do," Poonawalla told the newspaper. "The level of expectation and aggression is really unprecedented. It's overwhelming. Everyone feels they should get the vaccine. They can't understand why anyone else should get it before them," he said. The businessman indicated in the interview that his move to London is also linked to business plans to expand vaccine manufacturing to countries outside India, which may include the likes of the UK. "There's going to be an announcement in the next few days," he said, when asked about Britain as one of the production bases outside India. According to the newspaper, by the time the Oxford/AstraZeneca vaccine was approved in January this year, the Serum Institute of India had increased its annual production capacity from 1.5 to 2.5 billion doses at a cost of USD 800 million, and stockpiled 50 million doses of Covishield. The company began exporting to 68 countries, including Britain, as India seemed to have been over the worse, until the situation worsened in recent weeks. "We're really gasping for all the help we can get," Poonawalla said in the ‘Times' interview. "I don't think even God could have forecast it was going to get this bad," he said. On the charge of profiteering as the cost of Covishield was recently hiked, he termed it as "totally incorrect" and added that Covishield will still be "the most affordable vaccine on the planet" even at a higher price. "We have done the best we can without cutting corners or doing anything wrong or profiteering. I'll wait for history to judge," he said. "I've always had this sense of responsibility to India and the world because of the vaccines we were making, but never have we made a vaccine so needed in terms of saving lives," he added. Copyright © Jammu Links News Source: Jammu Links News
Covid vaccine as good in `real world` as in trial

Mexican Defense Minister tests COVID-19 positive

UK`s Prince Philip taken to hospital as `precaution`

75% vaccine under control of 10 countries: UN

Second shot of vaccination in India begins Feb 13

India continues with low daily Covid count; relaxation in gatherings
With 11,666 new COVID-19 cases reported in the last 24 hours, India on Thursday continued its streak of low single-day cases, health officials said. For the past 21 days, the country has been recording less than 20,000 daily new infections. Also, the death toll remained below 300-mark for the past 31 days.
Queen Elizabeth, husband Philip receive Covid-19 vaccine

India’s virus vaccination drive to begin Jan 16

World logs 14,792 more deaths, 826,719 new cases

India ready for rollout of Covid-19 vaccines within 10 days

India to export vaccine “within a few weeks”: BBC

Mexico approves AstraZeneca-Oxford virus vaccine

UK imposes 2nd phases lockdown after Covid-19 surge

India records 16,504 new COVID-19 cases, positivity rate dips to 5.89 per cent
JAN 04, 2021 NEW DELHI: Daily new COVID-19 cases in the country remained below 20,000 for the third consecutive day taking the virus caseload to 1,03,40,469, while higher testing has led to further decline in the cumulative positivity rate to 5.89 per cent, according to the Union Health Ministry data updated on Monday. A total of 16,504 people tested positive for coronavirus infection in a day. The daily new cases had last touched a low on December 29 last year with 16,432 new coronavirus infections being added to the national tally in a day after 187 days. The death toll increased to 1,49,649 with 214 new fatalities, the data updated at 8 am showed The number of people who have recuperated from the disease surged to 99,46,867 pushing the national recovery rate to 96.19 per cent, while the COVID-19 case fatality rate stands at 1.45 per cent. The COVID-19 active caseload remained below 3 lakh for the 14th consecutive day. There are 2,43,953 active cases of coronavirus infection in the country which comprise 2.36 per cent of the total caseload, the data stated. India''s COVID-19 tally had crossed the 20-lakh mark on August 7, 30 lakh on August 23, 40 lakh on September 5 and 50 lakh on September 16. It went past 60 lakh on September 28, 70 lakh on October 11, crossed 80 lakh on October 29, 90 lakh on November 20 and surpassed the one-crore mark on December 19. India''s total cumulative tests have crossed 17.5 crore (17,56,35,761) with 7,35,978 samples being tested on Sunday. "One crore tests were conducted in the last 11 days. Higher testing has led to further decline in the cumulative positivity rate at 5.89 per cent," the ministry highlighted. The 214 new fatalities include 35 from Maharashtra, 26 from West Bengal, 25 from Kerala, 16 from Uttar Pradesh and 14 each from Delhi, Chhattisgarh and Madhya Pradesh. A total of 1,49,649 deaths have been reported so far in the country including 49,666 from Maharashtra followed by 12,156 from Tamil Nadu, 12,107 from Karnataka, 10,585 from Delhi, 9,792 from West Bengal, 8,403 from Uttar Pradesh, 7,115 from Andhra Pradesh and 5,376 from Punjab. The health ministry stressed that more than 70 per cent of the deaths occurred due to comorbidities. "Our figures are being reconciled with the Indian Council of Medical Research," the ministry said on its website, adding that state-wise distribution of figures is subject to further verification and reconciliation. Copyright © Jammu Links News, Source: Jammu Links News


